A malignant neoplasm of the prostate is the medical term for prostate cancer. “Neoplasm” means an abnormal growth of cells, and “malignant” means those cells can invade surrounding tissue and spread to other parts of the body. You’ll typically see this phrase on pathology reports, medical records, or insurance documents rather than in everyday conversation. About 13 out of every 100 American men will develop prostate cancer during their lifetime, making it one of the most common cancers in men.
How Prostate Cancer Develops
The prostate is a walnut-sized gland that sits below the bladder and surrounds the urethra. It produces fluid that becomes part of semen. Prostate cells grow and divide under the influence of male hormones, particularly testosterone. When the DNA in prostate cells becomes damaged, those cells can begin multiplying out of control, forming a tumor. What makes the growth “malignant” rather than “benign” is its ability to break through the boundaries of the prostate and spread into nearby tissues or travel to distant organs, most commonly the bones.
Early-stage prostate cancer usually causes no symptoms at all. Many men have it without knowing. When the cancer grows large enough to press on the urethra or spreads locally, it can cause blood in the urine or semen, and persistent pain in the back, hips, or pelvis. These symptoms overlap with benign prostate conditions that are common with aging, so testing is needed to tell the difference.
Who Is Most at Risk
Age is the single biggest risk factor. Prostate cancer is rare in men under 40 and becomes increasingly common after 50. African American men face a disproportionately high risk: they are more likely to develop prostate cancer, tend to be diagnosed at a younger age with more advanced disease, and are more than twice as likely to die from it compared to other men.
Family history also matters significantly. Your risk increases if you have a first-degree relative (father, brother, or son) who had prostate cancer, especially if he was diagnosed before age 55. The risk climbs further if multiple family members across generations have been affected, or if relatives have had breast, ovarian, or pancreatic cancer, which can signal shared inherited genetic changes.
How It’s Detected
The most common initial screening tool is a blood test that measures prostate-specific antigen, or PSA. Normal PSA levels vary by age. For men between 40 and 50, levels up to 2.5 ng/ml are considered normal. That threshold gradually rises: up to 3.5 for men in their 50s, 4.5 in their 60s, and 5.5 in their 70s. A PSA level between 4 and 10 means roughly a 25% chance of cancer being present. Above 10, that chance rises above 50%.
An elevated PSA alone doesn’t confirm cancer. The next step is often an MRI of the prostate. Radiologists score suspicious areas on a 1-to-5 scale called PI-RADS: a score of 1 or 2 suggests cancer is unlikely, 3 is uncertain, and 4 or 5 indicates the area is highly suspicious. If imaging raises concern, a needle biopsy provides the definitive answer by examining actual tissue samples under a microscope.
Grading: How Aggressive the Cancer Is
When a biopsy confirms cancer, a pathologist examines the cells to determine how aggressive they are. They identify the two most common patterns of abnormal cells in the sample and assign each a grade from 3 to 5 (grades 1 and 2 are no longer used because those cell patterns aren’t considered cancer). These two grades are added together to produce a Gleason score ranging from 6 to 10. A Gleason score of 6 means slow-growing cancer with a low chance of spreading. A score of 10 indicates fast-growing cancer with a high chance of spreading.
Because the Gleason system can be confusing, doctors now also use a simpler five-tier Grade Group system based on the same information. Grade Group 1 (Gleason 6) is the least aggressive, with cells that typically grow slowly and are unlikely to spread. Grade Group 5 (Gleason 9-10) is the most aggressive. This numbering makes it more intuitive: starting at 1 instead of 6 gives patients a clearer sense of where their cancer falls on the spectrum.
Staging: How Far It Has Spread
Staging describes the physical extent of the cancer. The system uses T, N, and M categories to describe the tumor size, lymph node involvement, and whether the cancer has metastasized.
- T1: The tumor is too small to feel during a physical exam or see on imaging. It was found incidentally during another procedure or through a biopsy prompted by elevated PSA.
- T2: The tumor can be felt during a rectal exam but is still contained within the prostate. It may involve one side or both sides of the gland.
- T3: The cancer has grown through the outer layer of the prostate and may have reached the seminal vesicles (small glands attached to the prostate).
- T4: The cancer has invaded nearby structures such as the bladder, rectum, or pelvic wall.
N0 means nearby lymph nodes are clear; N1 means cancer has reached them. M0 means no distant spread; M1 means the cancer has metastasized to bones, distant lymph nodes, or other organs.
Survival Rates by Stage
Prostate cancer caught before it spreads has an excellent prognosis. The five-year relative survival rate for localized prostate cancer (confined to the prostate) is 100%. For regional disease (spread to nearby lymph nodes), it’s also 100%. These numbers reflect the fact that many prostate cancers grow slowly enough that men live full lifespans with appropriate management.
The picture changes with distant metastatic disease. When prostate cancer has spread to bones or distant organs, the five-year relative survival rate drops to about 40%, based on data from the National Cancer Institute’s SEER program covering 2016 through 2022. This is why early detection and monitoring matter so much.
Treatment Approaches
Treatment depends on the grade, stage, and how quickly the cancer appears to be growing. For low-grade, slow-growing cancers (Grade Group 1), many men are placed on active surveillance rather than immediate treatment. This means regular PSA tests, imaging, and periodic biopsies to monitor for any changes, with the understanding that treatment can begin if the cancer shows signs of becoming more aggressive.
For cancers that need treatment, the main options include surgery to remove the prostate and radiation therapy. Both aim to eliminate or destroy the cancer while it’s still localized.
Hormone therapy plays a central role in treating advanced prostate cancer. Because testosterone fuels the growth of prostate cancer cells, treatments that reduce testosterone levels or block its effects can slow or shrink the cancer. Some medications work by signaling the brain to stop telling the testicles to produce testosterone. Others block testosterone from attaching to cancer cells, essentially cutting off the fuel supply. A third category prevents testosterone from being produced not only in the testicles but also in the adrenal glands and within tumor tissue itself. In some cases, surgical removal of the testicles achieves the same goal, reducing blood testosterone by 90% to 95%.
Hormone therapy doesn’t cure prostate cancer permanently. Over time, cancer cells can adapt and begin growing without testosterone, a state called castration-resistant prostate cancer. At that point, newer medications that block hormone signaling more completely, chemotherapy, or other targeted treatments may be used.